Cabot Corp (CBT)

NYSEMaterialsChemicals - SpecialtySnapshot 2026-10-23

$73.79-0.73%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Cabot Corp’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2027 · Q1
Revenue	—	877M
EPS	—	1.59
FY 2026 · Annual
EPS	$6–$6.5non-GAAP	—
FY 2027 · Annual
Revenue	—	3.8B
EPS	—	6.986
FY 2028 · Annual
Revenue	—	3.94B
EPS	—	7.59

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain $1.3 billion unsecured revolving credit agreement	A supporting condition in Cabot Corp's published investment case. The stated target is maintain $1.3 billion credit facility.	Intact	credit facility reduced below $1 billion	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Cash flow from operations near $77M per quarter	The company keeps cash flow strong around $77M per quarter.	Under Pressure	cash flow falls below $70M per quarter	Cash from operations: $75M FY2026-Q3; GAAP. Published target: >=77 USD_MILLIONS per quarter. Target period is not explicitly aligned with this observation. Source published Aug 4, 202675,000,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q3 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q3. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
EPS near $6.25 in Q3 2026	EPS is guided near $6.25 in Q3 2026.	Under Pressure	EPS falls below $6.0 next quarter	Diluted EPS: $0.12 per share FY2026-Q3; GAAP. Published target: 6.25 USD_PER_SHARE. Target period ends 2026-09-30; this observation covers 2026-Q3. Source published Aug 4, 20260.12 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q3 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 184be440-1ad3-49ac-b5ed-69dd149886c9. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Operating income near $129M per quarter	The company keeps cash flow strong around $77M per quarter.	Intact	operating income falls below $120M per quarter	Operating income: $98M FY2026-Q3; GAAP. Published target: >=129 USD_MILLIONS per quarter. Target period is not explicitly aligned with this observation. Source published Aug 4, 202698,000,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q3 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 184be440-1ad3-49ac-b5ed-69dd149886c9. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-09-30 · fmp

FY2028 EPS: comparable history unavailable.

FY2028 revenue$3.94B

$3.92B → $3.94B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-10-01	Unavailable	$3,923,229,898	2 / 5
2026-10-02	Unavailable	$3,923,229,898	2 / 5
2026-10-03	Unavailable	$3,923,229,898	2 / 5
2026-10-04	Unavailable	$3,923,229,898	2 / 5
2026-10-05	Unavailable	$3,923,229,898	2 / 5
2026-10-06	Unavailable	$3,938,934,629	2 / 5
2026-10-07	Unavailable	$3,938,934,629	2 / 5
2026-10-08	Unavailable	$3,938,934,629	2 / 5
2026-10-09	Unavailable	$3,938,934,629	2 / 5
2026-10-10	Unavailable	$3,938,934,629	2 / 5
2026-10-11	Unavailable	$3,938,934,629	2 / 5
2026-10-12	Unavailable	$3,938,934,629	2 / 5
2026-10-13	Unavailable	$3,938,934,629	2 / 5
2026-10-14	Unavailable	$3,938,934,629	2 / 5
2026-10-15	Unavailable	$3,938,934,629	2 / 5
2026-10-16	Unavailable	$3,938,934,629	2 / 5
2026-10-17	Unavailable	$3,938,934,629	2 / 5
2026-10-18	Unavailable	$3,938,934,629	2 / 5
2026-10-19	Unavailable	$3,938,934,629	2 / 5
2026-10-20	Unavailable	$3,938,934,629	2 / 5
2026-10-21	Unavailable	$3,938,934,629	2 / 5
2026-10-22	Unavailable	$3,938,934,629	2 / 5
2026-10-23	Unavailable	$3,938,934,629	2 / 5
2026-10-24	Unavailable	$3,938,934,629	2 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	1	3	1
2026-06-01	2	3	1
2026-07-01	2	3	1
2026-08-01	2	3	1
2026-09-01	2	3	1
2026-10-01	2	3	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 2 Buy / Strong Buy · 3 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain $1.3 billion unsecured revolving credit agreementDirect metric needs a verified mapping
Cash flow from operations near $77M per quarterPublished status: Under Pressure
EPS near $6.25 in Q3 2026Published status: Under Pressure
Operating income near $129M per quarterOperating income: $98M

Next proof point

Nov 2, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.1%Typical daily move · historical

Downside history

-21.3%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Cabot Corp outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

CBT is an execution-dependent industrial materials business, not a clear turnaround or a high-confidence compounder on this evidence. Its long-term thesis is intact, and the recent signal improved, but management progress across key priorities remains mixed.

What's priced into Cabot Corp

CBT is described as cheap versus peers, while the valuation assessment says expectations are justified and fragility is low. The evidence does not show a large expectations gap, so the relative valuation alone does not establish that the market is overlooking weak execution.

What the fundamentals likely do

Near term, management is maintaining tighter fiscal 2026 adjusted earnings guidance, while quarterly results show some volatility. Battery Materials growth and planned manufacturing cost savings support the multi-year case, but Reinforcement Materials declines point to uneven execution. Sector conditions are a headwind, and the recent CEO transitions add uncertainty without a stated directional impact.

What Cabot Corp hinges on

The thesis depends on CBT delivering its fiscal 2026 guidance, growing Battery Materials, and making progress on cost savings. A guidance reversal after the recent increase would damage management credibility, while continued strength or weakness among sector bellwethers could shape the sector backdrop.

Bottom line

Over the next 1 to 3 years, CBT’s thesis remains intact but depends on steady delivery against mixed execution and sector risks. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.